CS
NYMX

Credit Suisse’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Credit Suisse’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,490
Closed -$2.23K – 3892
2022
Q4 		$2.23K Buy
+7,490
New +$2.71K ﹤0.01% 3546
2022
Q3 		– Sell
-30,000
Closed -$13K – 4449
2022
Q2 		$13K Hold
30,000
– – ﹤0.01% 3712
2022
Q1 		$38K Hold
30,000
– – ﹤0.01% 3523
2021
Q4 		$39K Sell
30,000
-14
-0% -$22 ﹤0.01% 4432
2021
Q3 		$62K Sell
30,014
-1,692
-5% -$3K ﹤0.01% 4339
2021
Q2 		$50K Sell
31,706
-4,045
-11% -$7.5K ﹤0.01% 4402
2021
Q1 		$80K Sell
35,751
-5,970
-14% -$15.7K ﹤0.01% 4205
2020
Q4 		$103K Buy
41,721
+11,285
+37% +$24.9K ﹤0.01% 4179
2020
Q3 		$75K Sell
30,436
-3,637
-11% -$10.6K ﹤0.01% 3943
2020
Q2 		$121K Buy
34,073
+495
+1% +$1.57K ﹤0.01% 3819
2020
Q1 		$78K Buy
33,578
+69
+0.2% +$194 ﹤0.01% 3868
2019
Q4 		$73K Buy
+33,509
New +$66.1K ﹤0.01% 4089
2019
Q3 		– Sell
-15,765
Closed -$23K – 4304
2019
Q2 		$23K Buy
+15,765
New +$27.6K ﹤0.01% 4044
2018
Q2 		– Sell
-11,672
Closed -$49K – 4195
2018
Q1 		$49K Buy
+11,672
New +$40.5K ﹤0.01% 3883
2017
Q4 		– Sell
-19,951
Closed -$76K – 4253
2017
Q3 		$76K Buy
+19,951
New +$75.6K ﹤0.01% 4124
2017
Q1 		– Sell
-28,359
Closed -$75K – 4142
2016
Q4 		$75K Buy
28,359
+8,017
+39% +$24.9K ﹤0.01% 3986
2016
Q3 		$66K Buy
20,342
+300
+1% +$981 ﹤0.01% 3986
2016
Q2 		$67K Sell
20,042
-40
-0.2% -$98 ﹤0.01% 4120
2016
Q1 		$49K Sell
20,082
-143
-0.7% -$338 ﹤0.01% 3888
2015
Q4 		$67K Sell
20,225
-14,076
-41% -$47.2K ﹤0.01% 4117
2015
Q3 		$118K Buy
+34,301
New +$79.8K ﹤0.01% 4077

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
CF
Corrigan Financial Middletown, Rhode Island $485M AUM 4.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAN
Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's NYMX Position: Q1 2023 in Review

Credit Suisse sold out of Nymox Pharmaceutical Corp (NYMX) in Q1 2023, closing a stake of 7,490 shares — an estimated $2.23K sold.

Credit Suisse first reported a position in NYMX in Q3 2015 and held it in 21 quarters. The position peaked at $121K in Q2 2020. 35 funds tracked by Wall St. Rank hold NYMX as of Q1 2023.

  • Credit Suisse reported no remaining Nymox Pharmaceutical Corp position as of Q1 2023 after selling out during the quarter.
  • Credit Suisse sold 7,490 Nymox Pharmaceutical Corp shares in Q1 2023, an estimated $2.23K.
  • Credit Suisse first reported a position in Nymox Pharmaceutical Corp in Q3 2015 and held it in 21 quarters.
  • Credit Suisse's Nymox Pharmaceutical Corp position peaked at $121K in Q2 2020.
  • 35 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.